Riskpilot← Back to searchSign inGet full accessOpIva Nordic AB
ABActiveOrg 5569777948Fiskebäcks Hamn 34Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20143 employees
Revenue 2025
SEK 21,8M
+15% vs 2024
EBITDA margin
14.9%
+31% vs 2024
Equity ratio
41.0%
Financial strength
Net profit 2025
SEK 2M
+1% vs 2024
| Revenue | SEK 21,8M | +15% |
| EBITDA | SEK 3,2M | +31% |
| Net profit | SEK 2M | +1% |
| Total assets | SEK 11,1M | +1% |
| Equity | SEK 4,6M | +10% |
| Employees | 3 | — |
Legal name
OpIva Nordic AB
Org number
5569777948
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16 juli 2014
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva handel med medicinteknisk utrustning till såväl offentlig som privat sjukvård och därmed förenlig verksamhet.
Address
Fiskebäcks Hamn 34
Email
mette.stahlgren@opivanordic.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 13 804 | 12 804 | 16 574 | 18 874 | 21 797 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 2 409 | 1 664 | 2 167 | 2 486 | 3 248 |
| Depreciation & amort. | −223 | −130 | −98 | −125 | −153 |
| EBIT | 2 186 | 1 534 | 2 069 | 2 361 | 3 095 |
| Net financials | — | −5 | −1 | −2 | −1 |
| Profit before tax | 1 774 | 1 644 | 2 307 | 2 569 | 2 584 |
| Tax | −375 | −352 | −517 | −565 | −566 |
| Net profit | 1 399 | 1 292 | 1 790 | 2 004 | 2 018 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 9 837 | 7 290 | 8 014 | 11 084 | 11 140 |
| Equity | 3 563 | 3 256 | 4 146 | 4 150 | 4 568 |
| Long-term debt | 262 | 0 | 2 | 2 | 0 |
| Short-term debt | 3 801 | 1 939 | 2 007 | 5 283 | 4 412 |
| Total debt | 4 063 | 1 939 | 2 009 | 5 285 | 4 412 |
EBITDA margin
14.9%
This company
15.8%
Market median
-6% vs market
20212025
Equity ratio
41.0%
This company
38.2%
Market median
+7% vs market
20212025
Return on equity
44.2%
This company
18.4%
Market median
+140% vs market
20212025
Net profit margin
9.3%
This company
8.1%
Market median
+15% vs market
20212025
Asset turnover
1.96×
This company
1.12×
Market median
+75% vs market
20212025
Debt / equity
1.44×
This company
0.62×
Market median
-132% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MN Chief Executive Officer | Chief Executive Officer | 2020 |
CO | Audit | 2022 |
| Former (1) | ||
SH Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OpIva Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Niclas Holmebäck | Chief Executive Officer | 0 companies |
| Carl Oscar Nils Bengtsson | Audit | 0 companies |
| Sara Helena Katarina Nilsson | Chief Auditor | 0 companies |
| Carl Gustav Jonasson | Board of Directors | 0 companies |
| Jens Per Alvar Lindblom Arvidsson | Deputy Board Member | 0 companies |
| Mette Caroline Ståhlgren | Chairman | 0 companies |